Latest Conference Articles

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

Yelena Y. Janjigian, MD, discusses updated results from the ​phase 2 DESTINY-Gastric01 trial​ in previously treated patients with HER2-positive gastric cancer.

Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.

Nilanjan Ghosh, MD, PhD, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B-cell non-Hodgkin lymphoma.

Justin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.

Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.

The neoadjuvant combination of nivolumab and ipilimumab continues to demonstrate a benefit in RFS compared with the combination given in the adjuvant setting in patients with stage III macroscopic melanoma.

Sheila Figel, PhD, a neuro-oncologic scientist with Roswell Park Comprehensive Cancer Center, discusses preclinical research with canonical and noncanonical that are displayed on the surface of cancer cells.

The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.

Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.

Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.

The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.

The oral modified dysfunctional tyrosine SM-88 has demonstrated antitumor activity and appears to broadly effect the immune dynamics of the tumor microenvironment, according to early data from 2 xenograft studies.

Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.

Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.

KRAS mutations are found in approximately in 25% of all NSCLC, and it was not until recently that the previously coined “undruggable target” showed signals of actionability with KRAS mutation–specific therapy, tumor-suppressor–specific therapy, and anti-inflammatory therapy.

Timothy Cragin Wang, MD, discusses the lack of response to checkpoint inhibitors in colorectal cancer.

The FDA is presently spearheading several initiatives in light of COVID-19 aimed at refining the role of RWD in cancer care to guide clinical trial development, procure answers to pressing clinical questions, and support regulatory decisions for in vitro diagnostics.

In urothelial carcinoma models, enfortumab vedotin-ejfv appeared to promote multiple mechanisms of action such as bystander cell killing, supporting the use of the agent either alone or in combination with pembrolizumab.

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.

Neal D. Shore, MD, FACS, discusses immunotherapy targeting prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in biochemically recurrent prostate cancer.

The combination of atezolizumab plus carboplatin/etoposide continued to demonstrate an improvement in overall survival versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer.

Tucatinib was found to be a potent inhibitor of HER2-mutant signaling in vitro.

Robert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.

Three main survivin isoforms demonstrated the ability to translocate to the surface of plasma membrane in multiple cell types, suggesting a targetable role as a molecular biomarker.

Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.

The use of adjuvant immunotherapy in patients with resected stage IIIC melanoma resulted in improved survival benefit, according to real-world data from an early analysis of the National Cancer Database.

Patients 18 to 39 years of age with early-onset cancer had a significantly high risk of harboring germline mutations, suggesting that this population should undergo germline genetic testing, irrespective of tumor type.